Personal fairness corporations TPG and Blackstone BX lately bid to amass Hologic Inc. HOLX, valuing the U.S. medical expertise firm at over $16 billion.
Hologic is an American medical expertise firm primarily targeted on ladies’s well being. It sells medical units for diagnostics, surgical procedure, and imaging.
Whereas Hologic rejected the preliminary nonbinding supply, citing sources, the Monetary Occasions writes that the negotiations might resume.
Benzinga reached out to Hologic for feedback.
Additionally Learn: FDA Warns Hologic Over BioZorb Manufacturing Violations
The proposed buyout valued Hologic between $16.3 billion and $16.7 billion, together with debt, and would have priced shares at $70 to $72—properly above the corporate’s closing worth of $54.28 on Friday.
The FT report provides that if profitable, the deal would have ranked among the many largest leveraged buyouts of the yr.
Regardless of the beneficiant premium, Hologic declined the method. Its inventory has dropped about 24% this yr, weighed down by U.S. tariffs and softening demand.
Hologic reported adjusted earnings of $1.03 per share for the second quarter of 2025, the identical as final yr, beating the consensus of $1.02. Gross sales decreased 1.2% yr over yr to $1.05 billion, beating the consensus of $1 billion.
Hologic lowered fiscal 2025 adjusted earnings per share steerage from $4.25-4.35 to $4.15-4.25 in comparison with consensus of $4.26, based mostly on tariffs and geopolitical circumstances.
The corporate reaffirmed gross sales steerage of $4.05 billion-$4.10 billion in comparison with the consensus of $4.08 billion.
Hologic expects third-quarter adjusted earnings of $1.04-1.07 per share versus consensus of $1.10 and gross sales of $1 billion-1.01 billion in comparison with the consensus of $1.03 billion.
The FT report famous that CEO MacMillan acknowledged within the firm’s latest quarterly earnings name that the enterprise had endured “a tumultuous few months from a macroeconomic and coverage perspective.” Nonetheless, it emphasised that the agency is making progress.
Hologic has lengthy been considered as a potential takeover goal. Activist investor Carl Icahn acquired a 12.5% stake in 2013, prompting the corporate to undertake a poison capsule technique. Icahn later secured two board seats and influenced management modifications, together with Steve MacMillan’s appointment as CEO.
Worth Motion: HOLX inventory is up 15.1% at $62.48 on the final verify Tuesday.
Learn Subsequent:
